HomeCompareOMGA vs MRK

OMGA vs MRK: Dividend Comparison 2026

OMGA yields 1402.52% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OMGA wins by $381345977.96M in total portfolio value
10 years
OMGA
OMGA
● Live price
1402.52%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$381345978.01M
Annual income
$334,438,358,870,850.44
Full OMGA calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — OMGA vs MRK

📍 OMGA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOMGAMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OMGA + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OMGA pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OMGA
Annual income on $10K today (after 15% tax)
$119,214.59/yr
After 10yr DRIP, annual income (after tax)
$284,272,605,040,222.90/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, OMGA beats the other by $284,272,605,031,894.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OMGA + MRK for your $10,000?

OMGA: 50%MRK: 50%
100% MRK50/50100% OMGA
Portfolio after 10yr
$190672989.04M
Annual income
$167,219,179,440,324.28/yr
Blended yield
87.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

OMGA
Analyst Ratings
6
Buy
1
Hold
Consensus: Buy
Price Target
$9.00
+6211.4% upside vs current
Range: $7.00 — $11.00
Altman Z
-5.0
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OMGA buys
0
MRK buys
0
No recent congressional trades found for OMGA or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOMGAMRK
Forward yield1402.52%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$381345978.01M$56.8K
Annual income after 10y$334,438,358,870,850.44$9,798.13
Total dividends collected$377907407.35M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$9.00$128.54

Year-by-year: OMGA vs MRK ($10,000, DRIP)

YearOMGA PortfolioOMGA Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$150,952$140,252.45$11,206$366.19+$139.7KOMGA
2$2,140,160$1,978,640.40$12,650$502.35+$2.13MOMGA
3$28,507,337$26,217,366.21$14,407$694.19+$28.49MOMGA
4$356,877,024$326,374,173.75$16,585$967.82+$356.86MOMGA
5$4,200,368,557$3,818,510,141.40$19,342$1,363.89+$4200.35MOMGA
6$46,497,265,746$42,002,871,390.15$22,913$1,947.19+$46497.24MOMGA
7$484,297,536,606$434,545,462,256.76$27,662$2,823.89+$484297.51MOMGA
8$4,748,158,615,450$4,229,960,251,282.26$34,159$4,173.35+$4748158.58MOMGA
9$43,838,896,396,104$38,758,366,677,572.48$43,337$6,308.80+$43838896.35MOMGA
10$381,345,978,014,682$334,438,358,870,850.44$56,776$9,798.13+$381345977.96MOMGA

OMGA vs MRK: Complete Analysis 2026

OMGAStock

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Full OMGA Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this OMGA vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OMGA vs SCHDOMGA vs JEPIOMGA vs OOMGA vs KOOMGA vs MAINOMGA vs JNJOMGA vs ABBVOMGA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.